Advancements in Cancer Care: RWJBarnabas and Rutgers Institute Showcase Groundbreaking Research at ASCO 2025
Innovative Cancer Research at ASCO 2025
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is set to gather influential clinicians and researchers from RWJBarnabas Health and Rutgers Cancer Institute, where they will unveil transformative findings in cancer research. The event will occur in Chicago from May 30 to June 3 and will be available online, bringing together experts to discuss recent innovations in oncology that may redefine patient care.
Key Highlights from the Research Presentations
With 45 accepted abstracts and various oral and poster presentations, this year's session promises to cover a vast spectrum of oncology research. Here are some focal points the audience can expect:
1. Psychosocial Support for Young Adults with Cancer
A significant study involving a multisite randomized trial, termed Bright IDEAS-Young Adults, examined problem-solving skills training. The findings revealed that participants experienced meaningful enhancements in depression and anxiety management and improved quality of life, aligning with greater problem-solving capabilities.
2. Impact of Geographic Barriers on Clinical Trial Participation
An extensive national analysis highlighted that individuals residing in areas categorized as food deserts or clinical trial deserts are less likely to enroll in breast cancer trials. Particularly, those living in both deserts showed a 27% less probability of participation, illustrating how socio-economic barriers significantly impede access to clinical trials.
3. Evaluation of HER2-Positive Breast Cancer Responses
Secondary results from the EA1181/CompassHER2 trial indicated that the neoadjuvant THP therapy resulted in a pathologic complete response (pCR) of 64% for specific HER2-positive cancers. The HER2DX pCR score was notably effective across ER statuses, offering a new predictive tool for cancer therapy outcomes.
4. The Repercussions of Tumor Biopsies in Clinical Trials
A focused study assessed whether requiring tumor biopsies affected patient enrollment in cancer studies. Results showed that over 42% of participants in phase I trials had at least one biopsy. Surprisingly, patients who underwent biopsies faced a treatment initiation delay of a median of six days, raising questions about the logistical constraints of trial-related procedures.
5. Outcomes for Metastatic Colorectal Cancer Patients
Research involving 283 patients with metastatic colorectal cancer (mCRC) demonstrated an overall survival rate comparable to standard treatments. The findings also pointed towards a non-significant trend linking a greater number of previous therapies to shorter overall survival, adding an additional layer to patient management considerations.
6. Liquid Biopsy in Unknown Primary Cancer
In a groundbreaking review of over 13,000 patients, researchers found that nearly 30% had detectable targetable genetic mutations through liquid biopsy, which matches tissue-testing efficacy. This revelation carries potential implications for personalized treatment approaches and calls for further studies on the implications of these mutations.
A Commitment to Cancer Care
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, RWJBarnabas Health and Rutgers Cancer Institute embody a profound dedication to advancing cancer treatment. According to Steven K. Libutti, MD, FACS, the strength of their research team, coupled with the recent inauguration of the Jack Sheryl Morris Cancer Center — New Jersey's first freestanding cancer hospital — marks a pivotal moment in their journey to enhance patient care.
The comprehensive cancer treatment options include cutting-edge technologies and therapies such as CAR T-cell therapy, proton therapy, and precision medicine — innovations not widely accessible elsewhere. The ASCO Annual Meeting will serve as an essential platform for sharing additional insights that could reshape the future of oncology.
For more information on the presentations and findings from the 2025 ASCO Annual Meeting, please visit the official ASCO website or the Rutgers Cancer Institute web page.
Contact Information
For media inquiries, please reach out to Krista Didzbalis at RWJBarnabas Health, or for patient appointments, call 844-CANCERNJ.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.